POPULARITY
John Hallick, founder and president of MET Crusaders and co-president of Biomarker Collaborative, joins the podcast to share the story of his journey into patient advocacy. In February 2018, John was diagnosed with stage IV non-small cell lung cancer. Several weeks later, the genetic tests came back, and the cancer was determined to be driven by the MET 14 skipping alteration. After learning from doctors that while there are many support groups for genetic alterations, there was none for his, John took action. He drew from his background as a serial entrepreneur to set up a patient-centric advocacy group for people with his particular genetic alteration. You'll hear about:John's story from his diagnosis of stage IV metastatic cancer to his treatment to where he is todayMET Crusaders, the advocacy group John founded that's dedicated to helping patients with the MET alteration live normal lives Biomarker Collaborative, a comprehensive body that represents all the advocacy groups, and their work connecting patients with the resources and support they need during what is likely the most traumatic point in their life How others can find support and resourcesMost importantly, you'll meet a courageous individual who is using his own serious life challenge as a springboard to help, educate, and support others.https://biomarkercollaborative.org/John Hallick is a serial entrepreneur of several companies, all based around data warehousing, data mining, and individualized communications management. In December 2017, John developed what he thought might be the flu. It was diagnosed as an upper respiratory infection, and he was prescribed an antibiotic. After several weeks, the symptoms didn't go away, and he went back to the doctor's office. The second diagnosis was bronchitis, and he was prescribed prednisone. Again, the illness never went away. In January of 2018, he flew a helicopter four hours from Madison, WI, to Louisville, KY. The drive back to Madison was eight hours. He coughed on and off the entire drive back home. The next day, he went back to the doctor, and they decided to take an X-ray. The X-ray showed he had a mass in his right lung. As a note, nine months earlier he had a normal chest X-ray. At the end of January 2018, the Mayo Clinic in Rochester, MN, performed a complete workup, including PET scans, CT scans, brain MRIs, bone scans, and blood work. On February 1, 2018, at age 67, John was diagnosed with stage IV non-small cell lung cancer. Several weeks later, the genetic tests came back, and the cancer was determined to be driven by the MET 14 skipping alteration. His initial treatment was a combination of carboplatin, Alimta, and Keytruda every three weeks. John experienced all the normal side effects, including losing 65 pounds and half his hair, hearing loss, neuropathy on the bottom of his feet, no energy, and a significant loss of red blood cells. He was given two units of blood to get his red blood cells back into range. After four treatment sessions, carboplatin was removed from his treatment due to intolerability. After a total of five months of mixed results, it was decided for him to have one additional treatment and look for a clinical trial. After the last treatment, the immunotherapy started to work, and the tumors shrunk about one-third. Now John had to make the decision of whether to stay on the current treatment plan or go on the trial. John decided to go on the capmatinib phase 2 clinical trial in July 2018. At first, the tumors shrank and then became stable. Targeted therapy returned his quality of life. Like all TKIs, capmatinib stayed effective for over three-and-a-half years. John trialed a MET antibody with limited success and is back on chemo and immune therapy.
Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up: She developed the company concept and has spearheaded fundraising efforts, and today, she continues to lead Aura's strategy and operations. Prior to founding Aura, she worked in Eli Lilly & Co.'s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School. She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal's 2009 “Top 40 under 40” list; as a Mass High Tech “Woman to Watch” in 2010; as a “Technology Pioneer” by the World Economic Forum in 2010; and as one of Goldman Sachs' “100 Most Intriguing Entrepreneurs” in 2014.
After being diagnosed with Stage 3B lung cancer, Gary Brausen went through a painful journey that included radiation, aggressive chemotherapy and the loss of a lung; but he survived, and now works hard to help others with their cancer journeys.
MesoTV Podcast: Conversations Impacting the Mesothelioma Community
Dr. Andreas Rimner of Memorial Sloan Kettering Cancer Center joins us to discuss a clinical trial "Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma." Dr. Rimner is a radiation oncologist specializing in thoracic cancers. He in interviewed by Mary Hesdorffer, expert nurse practitioner and executive director of the Mesothelioma Applied Research Foundation. Patients who need help with their diagnosis can contact Mary Hesdorffer, NP through the organization's website. The Mesothelioma Applied Research Foundation is the only national nonprofit organization dedicated to eradicating mesothelioma by providing patient services and education; funding peer-reviewed research; and advocating for government funding of mesothelioma research. More information about the organization is available at www.curemeso.org.
Robert was lifting weights at his local YMCA before a routine doctor's appointment revealed he had stage 4 lung cancer.Robert's doctor estimated he only had one year to live. Following nine months of chemo- radiation, Robert's cancer went into remission. However, after only one month the cancer returned.Although a native of Alabama, Robert's wife and her family are from New England and recommended Robert seek treatment at Dana-FarberSince then, Robert has been under the care of Dr. Chris Lathan and his team.Robert started in an immunotherapy clinical that lasted for two years. He was removed from the trial in May 2018 due to the cancer's progression and is not being treated with Alimta. His scans have shown positive momentum. Throughout his treatment Robert thanks his wife, who has been there for him throughout it all.Dr. Christopher Lathan is an oncologist who specializes in cancers of the chest, including lung cancer.He sees patients and has published many research papers, mainly on cancer disparities for minorities.As Faculty Director for the Cancer Care Equity program at Dana-Farber, Dr. Lathan is committed to providing better access to cancer care and education to Boston communities.
Today in FirstWord:
Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.
Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.
Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Elisabeth “Eli” de los pinos was enjoying her job at Eli Lilly’s Oncology Business Unit where she was part of the leadership team responsible for Alimta’s market launch in Europe, a new drug for the treatment of Lung cancer. But she took the leap, leaving corporate comfort to build Aura Biosciences from the ground up around viral-like synthetic nanoparticles that are closely related to wild type viruses in structure and behavior but lack any viral DNA. These empty protein shells resemble viruses but do not have the capability to replicate or integrate. Aura is leverage the technology to create AU-011, which can deliver potent cell-killing laser-activated molecule right to the point of ocular cancer. Aura says the molecule is activated by a standard ophthalmologic laser and treatment will be administered in an outpatient visit.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.
The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.
The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.
Today in FirstWord:
Today in FirstWord:
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014
Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014
Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
Today in FirstWord:
Today in FirstWord:
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Jack West describes the factors that contribute to a recommendation for or against post-operative (adjuvant) chemotherapy for a patient with resected early stage non-small cell lung cancer.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, with this podcast focusing on ALK rearrangements and new molecular targets in lung cancer.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, with this podcast focusing on ALK rearrangements and new molecular targets in lung cancer.
Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.
Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.
Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for an ex-smoker with a lung adenocarcinoma.
Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for an ex-smoker with a lung adenocarcinoma.
Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for a patient with advanced squamous cell NSCLC.
Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for a patient with advanced squamous cell NSCLC.